Floatz logo

LAMOTRIGINE

Alcohol Dependence

Medical University of South CarolinaSmall moleculePhase 4 / ApprovedDormant
BB
68/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
54/ 100
Competitive Position
89/ 100

Competitive context

8 Active assets in the Alcohol Dependence cohort.

Asset / SponsorPhaseRating
Naltrexone
Inventage Lab., Inc.
Phase 4BBB
Acamprosate
Hanyang University Seoul Hospital
Phase 4BBB
Cipralex
University of Texas Southwestern Medical Center
Phase 4BBB
Seroquel®
University of Texas Southwestern Medical Center
Phase 4BBB
Topamax
Stanford University
Phase 4BB

View all 27 →

Same molecule, other indications

LAMOTRIGINE is also rated in:

focal epilepsyDormant
BBB
Indicative ·
79 / 100
View asset →
epilepsy with generalized tonic-clonic seizuresDormant
BBB
Indicative ·
75 / 100
View asset →
bipolar disorderDormant
BBB
Indicative ·
74 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →